Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus JNJ-77242113: n tehokkuuden ja turvallisuuden arvioimiseksi verrattuna lumelääkkeeseen ja utstekinumabiin osallistujilla, joilla on kohtalainen tai vaikea plakin psoriaasi (ICONIC-ASCEND)

maanantai 2. marraskuuta 2026 päivittänyt: Janssen Research & Development, LLC

Vaiheen 3 monikeskus, satunnaistettu, kaksoissokkoutettu, lumelääkekontrolloima ja ustekinumab aktiivinen vertailun kontrolloima tutkimus JNJ-77242113: n tehokkuuden ja turvallisuuden arvioimiseksi osallistujien hoidossa kohtalaisesta vakavaan plakin psoriaasiin.

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

752

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Barrio Gral Paz Cba Capital, Argentiina, X5000
        • Consultora Integral de Salud SRL
      • Buenos Aires, Argentiina, B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, Argentiina, C1417EYG
        • Mindout Research
      • Buenos Aires, Argentiina, C1425
        • Instituto de Neumonologia y Dermatologia
      • CABA, Argentiina, C1061AAS
        • CIPREC
      • CABA, Argentiina, C1199ABB
        • Hospital Italiano de Buenos Aires
      • CABA, Argentiina, C1055AAO
        • Buenos Aires Skin
      • CABA, Argentiina, C1056ABH
        • Investigaciones Medicas IMOBA SRL
      • CABA, Argentiina, C1128
        • Mautalen Salud e Investigacion
      • Caba, Argentiina, C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • Rosario, Argentiina, S2000DBS
        • Instituto De Especialidades De La Salud SRL
      • San Fernando, Argentiina, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, Argentiina, T4000
        • Instituto de Investigaciones Medicas Tucuman
      • Clayton, Australia, 3168
        • Monash Medical Centre
      • Coorparoo, Australia, 4151
        • Cornerstone Dermatology
      • Greenslopes, Australia, 4120
        • Veracity Clinical Research
      • Kogarah, Australia, 2217
        • Premier Specialists
      • Melbourne, Australia, 3004
        • The Alfred Hospital
      • Melbourne, Australia, 3050
        • Royal Melbourne Hospital
      • Mitcham, Australia, 3132
        • ISHI dermatology
      • Westmead, Australia, 2145
        • Westmead Hospital
      • Brussels, Belgia, 1090
        • UZ Brussel
      • Ghent, Belgia, 9000
        • Ghent University Hospital
      • Ghent, Belgia, 9000
        • AZ St. Lucas
      • Leuven, Belgia, 3000
        • Universitair Ziekenhuis Leuven
      • Liège, Belgia, 4000
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Maldegem, Belgia, 9990
        • Dermatologie Maldegem
      • Alicante, Espanja, 03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo, Espanja, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, Espanja, 08036
        • Hosp. Clinic de Barcelona
      • Granada, Espanja, 18016
        • Hosp. Univ. San Cecilio
      • Madrid, Espanja, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Espanja, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, Espanja, 28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Manises, Espanja, 46940
        • Hosp. de Manises
      • Santiago Compostela, Espanja, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, Espanja, 41009
        • Hosp. Virgen Macarena
      • Seville, Espanja, 41014
        • Hosp. Ntra. Sra. de Valme
      • Valencia, Espanja, 46026
        • Hosp. Univ. I Politecni La Fe
      • Villajoyosa, Espanja, 03570
        • Hosp. de La Marina Baixa
      • Zaragoza, Espanja, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Zaragoza, Espanja, 50009
        • Hosp. Univ. Miguel Servet
      • Feldkirch, Itävalta, 6800
        • LKH Feldkirch
      • Linz, Itävalta, 4020
        • Kepler Universitatsklinikum GmbH
      • Sankt Pölten, Itävalta, 3100
        • Universtitatsklinikum St Poelten
      • Vienna, Itävalta, 1090
        • Allgemeines Krankenhaus der Stadt Wien
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1E 1V4
        • Skincare Studio Inc Dermatology Clinical Trials
    • Ontario
      • Ajax, Ontario, Kanada, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, Kanada, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, Kanada, L8N 1Y2
        • Dermatrials Research
      • London, Ontario, Kanada, N6A 5R9
        • Lovegrove Dermatology
      • Markham, Ontario, Kanada, L3P 1X3
        • Lynderm Research Inc.
      • Waterloo, Ontario, Kanada, N2J 1C4
        • Alliance Clinical Trials
    • Quebec
      • Montreal, Quebec, Kanada, H2X 2V1
        • Innovaderm Research Inc.
      • Québec, Quebec, Kanada, G1W 4R4
        • The Centre de recherche Saint-Louis
      • Guimarães, Portugali, 4835 044
        • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
      • Leiria, Portugali, 2410 197
        • Unidade Local De Saude Da Regiao De Leiria Epe
      • Lisbon, Portugali, 1169 050
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, Portugali, 1998 018
        • Hosp. Cuf Descobertas
      • Porto, Portugali, 4099 001
        • Ulssa Hosp. Santo Antonio
      • Bialystok, Puola, 15 375
        • Specderm Poznanska sp j
      • Bialystok, Puola, 15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Elblag, Puola, 82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Katowice, Puola, 40 568
        • Care Clinic Sp z o o
      • Krakow, Puola, 30 002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz, Puola, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Olsztyn, Puola, 10-117
        • Etyka Osrodek Badan Klinicznych
      • Poznan, Puola, 60 529
        • SOLUMED Centrum Medyczne
      • Skierniewice, Puola, 96 100
        • Velocity Nova Sp z o o
      • Warsaw, Puola, 02 661
        • Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
      • Warsaw, Puola, 02 953
        • Klinika Ambroziak Dermatologia
      • Wroclaw, Puola, 52 416
        • Centrum Medyczne Oporow
      • Wroclaw, Puola, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Augsburg, Saksa, 86179
        • Klinikum Augsburg
      • Bad Bentheim, Saksa, 48455
        • Fachklinik Bad Bentheim
      • Berlin, Saksa, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bonn, Saksa, 53127
        • Universitatsklinikum Bonn
      • Bramsche, Saksa, 49565
        • Studienzentrum an der Hase GbR
      • Darmstadt, Saksa, 64283
        • Rosenpark Research GmbH
      • Dresden, Saksa, 01307
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Friedrichshafen, Saksa, 88045
        • Derma-Study-Center Friedrichshafen GmbH
      • Kiel, Saksa, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau, Saksa, 89129
        • Studienzentrum Dr Schwarz Germany
      • Mahlow, Saksa, 15831
        • Dermatologie Mahlow
      • Mainz, Saksa, 55128
        • Gemeinschaftspraxis Dres. Quist
      • Münster, Saksa, 48149
        • Universitaetsklinikum Muenster
      • Witten, Saksa, 58453
        • Hautarztpraxis
      • Aalborg, Tanska, 9100
        • Aalborg Sygehus Syd
      • Aarhus, Tanska, 8200
        • Aarhus University Hospital
      • Hellerup, Tanska, 2900
        • Gentofte Hospital
      • København NV, Tanska, 2400
        • Bispebjerg Hospital
      • Odense, Tanska, 5000
        • Odense University Hospital
      • Roskilde, Tanska, 4000
        • Sjællands University hospital
      • Budapest, Unkari, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, Unkari, 1152
        • Uno Medical Trials Ltd.
      • Debrecen, Unkari, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, Unkari, 4031
        • Derma-B Kft
      • Gyula, Unkari, 5700
        • Synexus Magyarorszag Kft
      • Gyöngyös, Unkari, 3200
        • Gyongyosi Bugat Pal Korhaz
      • Hódmezővásárhely, Unkari, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kaposvár, Unkari, 7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Kecskemét, Unkari, 6000
        • Bacs-kiskun Megyei Korhaz
      • Szolnok, Unkari, 5000
        • Allergo-Derm Bakos Kft.
      • Veszprém, Unkari, 8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
      • Dudley, Yhdistynyt kuningaskunta, DY1 2HQ
        • Dudley Group NHS Foundation Trust
      • Harrow, Yhdistynyt kuningaskunta, HA1 3UJ
        • London North West University Healthcare NHS Trust
      • Kings Lynn, Yhdistynyt kuningaskunta, PE30 4ET
        • The Queen Elizabeth Hospital NHS Foundation Trust
      • London, Yhdistynyt kuningaskunta, SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading, Yhdistynyt kuningaskunta, RG1 5AN
        • Royal Berkshire Hospital
      • Salford, Yhdistynyt kuningaskunta, M6 8HD
        • Salford Royal Hospital
      • Southampton, Yhdistynyt kuningaskunta, So166yd
        • University Hospital Southampton
      • Wakefield, Yhdistynyt kuningaskunta, WF1 4DG
        • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
    • Alabama
      • Birmingham, Alabama, Yhdysvallat, 35244
        • Cahaba Research Inc
    • California
      • Encinitas, California, Yhdysvallat, 92024
        • California Dermatology & Clinical Research Institute
      • Encino, California, Yhdysvallat, 91436
        • T Joseph Raoof Md Inc
      • Fountain Valley, California, Yhdysvallat, 92708
        • First OC Dermatology
      • Oceanside, California, Yhdysvallat, 92056
        • Dermatologist Medical Group of North County, Inc.
      • Rocklin, California, Yhdysvallat, 95765
        • NorCal Clinical Research
      • Sacramento, California, Yhdysvallat, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Yhdysvallat, 92103
        • MedDerm Associates
      • Santa Ana, California, Yhdysvallat, 92701
        • Southern California Dermatology
      • Sylmar, California, Yhdysvallat, 91342
        • Olive View-UCLA Education & Research Institute
    • Connecticut
      • Farmington, Connecticut, Yhdysvallat, 06030
        • University of Conn Health Center
    • Florida
      • Miami, Florida, Yhdysvallat, 33155
        • Bioclinical Research Alliance Inc.
      • Miami, Florida, Yhdysvallat, 33126
        • Driven Research LLC
      • Ocala, Florida, Yhdysvallat, 34470
        • Renstar Medical Research
      • Tampa, Florida, Yhdysvallat, 33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta, Georgia, Yhdysvallat, 30022
        • Hamilton Research LLC
    • Illinois
      • Skokie, Illinois, Yhdysvallat, 60076
        • Northshore Medical Group
    • Indiana
      • Plainfield, Indiana, Yhdysvallat, 46168
        • Indiana Clinical Trial Center
    • Iowa
      • Iowa City, Iowa, Yhdysvallat, 52242
        • University of Iowa
    • Kentucky
      • Bowling Green, Kentucky, Yhdysvallat, 42104
        • Equity Medical
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02111
        • Tufts Medical Center
      • Brighton, Massachusetts, Yhdysvallat, 02135
        • Metro Boston Clinical Partners
    • Michigan
      • Caledonia, Michigan, Yhdysvallat, 49316
        • The Derm Institute of West Michigan
      • Detroit, Michigan, Yhdysvallat, 48202
        • Henry Ford Hospital
      • Fort Gratiot, Michigan, Yhdysvallat, 48059
        • Hamzavi Dermatology
      • Troy, Michigan, Yhdysvallat, 48084
        • Somerset Skin Centre
    • Minnesota
      • New Brighton, Minnesota, Yhdysvallat, 55112
        • Minnesota Clinical Study Center
    • Missouri
      • Kirksville, Missouri, Yhdysvallat, 63501
        • Cleaver Dermatology
      • Saint Joseph, Missouri, Yhdysvallat, 64506
        • MediSearch Clinical Trials
    • New York
      • New York, New York, Yhdysvallat, 10075
        • Sadick Research Group
      • New York, New York, Yhdysvallat, 10028
        • Mount Sinai Doctors Dermatology
    • North Carolina
      • Wilmington, North Carolina, Yhdysvallat, 28405
        • Wilmington Dermatology Center
    • Ohio
      • Boardman, Ohio, Yhdysvallat, 44512
        • Optima Research
      • Mayfield Heights, Ohio, Yhdysvallat, 44124
        • Apex Dermatology Mayfield Heights
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, Yhdysvallat, 97201
        • Oregon Medical Research Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Yhdysvallat, 19114
        • Clinical Research Philadelphia
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15213
        • UPMC Department of Dermatology
    • South Dakota
      • Rapid City, South Dakota, Yhdysvallat, 57702
        • Health Concepts
    • Tennessee
      • Nashville, Tennessee, Yhdysvallat, 37211
        • Advanced Research Experts PLLC
    • Texas
      • Arlington, Texas, Yhdysvallat, 76011
        • Arlington Research Center, Inc.
      • Dallas, Texas, Yhdysvallat, 75231
        • Modern Research Associates PLLC
      • Houston, Texas, Yhdysvallat, 77004
        • Center for Clinical Studies 1
      • San Antonio, Texas, Yhdysvallat, 78218
        • Texas Dermatology and Laser Specialists
      • San Antonio, Texas, Yhdysvallat, 78213
        • Progressive Clinical Research
      • Webster, Texas, Yhdysvallat, 77598
        • Center for Clinical Studies
    • Utah
      • West Valley City, Utah, Yhdysvallat, 84120
        • Kalo Clinical Research
    • Washington
      • Mill Creek, Washington, Yhdysvallat, 98012
        • Frontier Derm Partners CRO, LLC

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

12 vuotta ja vanhemmat (Lapsi, Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Placebo Comparator: Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Matching placebo will be administered orally.

Active Comparator: Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

JNJ-77242113 will be administered orally.

Matching placebo will be administered orally.

Ustekinumab will be administered subcutaneously.

Muut nimet:
  • STELARA
  • CNTO 1275

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Aikaikkuna: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Aikaikkuna: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Aikaikkuna: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Aikaikkuna: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Aikaikkuna: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Aikaikkuna: Week 28

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Aikaikkuna: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Aikaikkuna: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Aikaikkuna: Week 16

PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Aikaikkuna: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Aikaikkuna: Up to Week 108

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important.

Up to Week 108
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Aikaikkuna: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Aikaikkuna: Baseline up to Week 16

DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Aikaikkuna: Week 16

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Aikaikkuna: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Aikaikkuna: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Aikaikkuna: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Aikaikkuna: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Aikaikkuna: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Aikaikkuna: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Aikaikkuna: Baseline up to Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Aikaikkuna: Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Aikaikkuna: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Aikaikkuna: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Aikaikkuna: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Aikaikkuna: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 15. huhtikuuta 2025

Ensisijainen valmistuminen (Todellinen)

Maanantai 17. marraskuuta 2025

Opintojen valmistuminen (Arvioitu)

Perjantai 20. elokuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 11. huhtikuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 11. huhtikuuta 2025

Ensimmäinen Lähetetty (Todellinen)

Perjantai 18. huhtikuuta 2025

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 3. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 77242113PSO3006
  • 77242113PSO3006 (Muu tunniste: Janssen Research & Development, LLC)
  • 2024-515706-77-00 (Rekisterin tunniste: EUCT number)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Yhdysvalloissa valmistettu ja sieltä viety tuote

Joo

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa